PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

PEGS Boston – 17/02/2025
NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
Aurisco – 04/02/2025

ReNeuron climbs on updated vision loss cell therapy data

Eye
ReNeuron’s stock price has risen by more than 300% over the past month. (Unsplash)

ReNeuron has reported further improvements in the vision of patients treated with its cell therapy. The mean increase in visual acuity across the three retinitis pigmentosa (RP) patients now stands at 23 letters, well above the level deemed clinically meaningful by the FDA.

British biotech ReNeuron is testing its human retinal progenitor cell therapy candidate in advanced RP patients with some remaining retinal function. ReNeuron initiated the trial to validate its belief that the cells preserve existing photoreceptors and mature into functional photoreceptors, thereby preserving and possibly restoring vision.

An early look at data on three patients provided preliminary support for that hypothesis in February. Now, updated data on the same subjects has suggested the cells may drive ongoing improvements in vision, at least up to 60 days after treatment.

ReNeuron now has 120 days of follow-up on one subject and 60 days on the other two. As of those cutoffs, the subjects could, on average, see 23 letters more on a standard vision chart than before being treated with the progenitor cells, compared to an improvement of five letters in the untreated eyes. The improvements ranged from 21 letters in one patient to 23 in another.

The first subject enrolled in the trial could see nine letters at baseline. Sixty days after treatment, the figure increased to 29 letters. Beyond that, there are signs that the effect may have plateaued, with the subject gaining one more letter of vision over the following 60 days.

Data on the other two patients suggest vision continues to improve from day 18 to day 60. Over that period, the vision of the second and third subjects improved by 10 letters and nine letters, respectively. The third subject had better vision at baseline than the other two patients—32 letters versus nine letters—but achieved a comparable improvement following treatment.

Shares in ReNeuron jumped 20% following the news, accelerating the upward trajectory of the stock. ReNeuron’s stock price has risen by more than 300% over the past month, bringing it back up to levels it last hit in 2016.

To maintain and build on those gains, ReNeuron will need to test its cells in more patients and show the effects seen over the first 120 days are durable. If ReNeuron does so, it could have a product capable of winning over the FDA, which views improvements of 15 letters or more as clinically meaningful.

Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40